Revium Rx Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Amir Avraham
Chief executive officer
US$91.0k
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 1.1yrs |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$14m |
| Dec 31 2025 | US$91k | US$91k | -US$13m |
| Sep 30 2025 | n/a | n/a | -US$2m |
| Jun 30 2025 | n/a | n/a | -US$2m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | US$49k | US$41k | -US$4m |
Compensation vs Market: Amir's total compensation ($USD91.00K) is below average for companies of similar size in the US market ($USD648.55K).
Compensation vs Earnings: Amir's compensation has increased whilst the company is unprofitable.
CEO
Amir Avraham (49 yo)
Mr. Amir Avraham, CPA, was Chief Financial Officer & General Manager of OCON Medical Ltd. Mr. Amir Avraham, CPA served as Interim Chief Executive Officer of Revium Rx. (formerly known as Revium Recovery In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.1yrs | US$91.00k | no data | |
| Consultant | no data | US$271.50k | 4.57% $ 4.6m | |
| Chief Financial Officer | less than a year | no data | no data |
Experienced Management: RVRC's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Director | 1.3yrs | US$90.50k | 5.23% $ 5.3m | |
| Independent Director | 5.3yrs | US$12.20k | no data | |
| Director | 3yrs | US$48.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: RVRC's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/27 04:37 |
| End of Day Share Price | 2026/03/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revium Rx. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.